Ozempic, Wegovy and Your Eyes: What Europe’s 2025 Ruling on NAION Really Means

By Patrick Lancier

Lede. In June 2025 the European Medicines Agency reached a decision that matters to millions: NAION, a rare optic-nerve condition, is a “very rare” side effect of semaglutide, the molecule in Ozempic and Wegovy. Measured, not alarmist — the risk is small, but one symptom should send you to an eye specialist fast.

TL;DR: NAION = sudden, painless vision loss, usually one eye; EMA “very rare” (up to 1/10,000); ~double risk in diabetics per some studies; causation not proven; warning sign = sudden vision change → urgent eye care, don’t stop the drug yourself.

What is NAION?

Non-arteritic anterior ischemic optic neuropathy = reduced blood flow to the optic-nerve head; painless, often sudden vision loss in one eye, sometimes on waking. No established cure → early recognition matters.

Why did regulators act?

A 2024 JAMA Ophthalmology study reported a hazard ratio around 4 in a small, selected group. Replications were mixed: a Danish cohort of more than 400,000 people found roughly double the 5-year risk, while a large US matched database found no significant difference. The EMA’s PRAC concluded on 6 June 2025.

What the decision says

“Very rare” (up to 1/10,000); added to the product information for Ozempic, Wegovy and Rybelsus. An association was observed but causation is not established; benefits still outweigh risks. The WHO echoed this in late June 2025.

The warning sign

Seek care immediately for sudden vision loss or rapidly worsening eyesight, especially in one eye. An urgent eye assessment is needed. If NAION is confirmed, whether to stop semaglutide is decided case by case — your doctor’s call.

Same molecule, two names

Ozempic (diabetes, up to 2 mg/week) and Wegovy (obesity, 2.4 mg/week) share the same active substance; the decision applies to both. The differences are dose and indication.

FAQ

Can they cause blindness? NAION can seriously affect one eye’s vision; it is very rare and causation is unproven.

What are the warning signs? Sudden painless vision loss or fast-worsening sight → urgent eye care.

Should I stop my medication? Never on your own; it’s your doctor’s call.

What if I’m worried? Note your symptoms, book your doctor, and report visual changes promptly.

Sources: EMA/PRAC (6 June 2025); JAMA Ophthalmology (2024); American Journal of Ophthalmology (2025); Danish cohort (2024); WHO (27 June 2025); FDA labels Ozempic/Wegovy (2025).